The Copenhagen-based team is building an AI platform to target underexplored GPCRs to treat diseases once deemed undruggable.

Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets and based on stabilized helical peptides or Helicons, has filed for an IPO.

By developing their own functional nerves, these organoids demonstrate how engineering principles can drive biological ...

Roughly 2700 attendees heard a range of perspectives from experts in precision medicine, bioinformatics, and rare disease ...

Researchers suggest targeting mTOR activity in aggressive cancers by blocking cholesterol sensing may represent a promising ...

By mapping how genes relate to one another across biological situations, GSFM creates a reference framework that can help ...

Transcriptomics of two prevailing models, cuprizone (CPZ) and lysophosphatidylcholine (LPC), reveal understanding of myelin loss and regeneration.

New approach recruits the body’s immune system to attack glioblastoma while reducing treatment-related toxicity.

One of CRS’ first customers is SRTD Biotech, an emerging biotech in Germany, which is starting small scale on novel ...

Wisconsin Governor Tony Evers (center) leads the ribbon-cutting ceremony at FUJIFILM Cellular Dynamics’ new headquarters and manufacturing facility in Madison, WI. [FUJIFILM Cellular Dynamics] In ...

Study found that EPAC2 levels appear to rise gradually as the brain matures, suggesting it may have particular relevance as a ...

Biotech companies that use CDD Vault will be able to utilize select Lilly predictive models within their natural scientific ...